Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 10/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.79 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.79 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | HTR1D | P28221 | 4/20 | 0.79 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
| ▸ | HRH2 | P25021 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.79 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.79 |
| ▸ | HTR1A | P08908 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL29355529 | 0.90 | ADRA2A (0.64) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| Clonidine SCHEMBL5983 | 0.89 | ADRA2A (1.00) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL4760243 | 0.89 | HTR1D (1.00) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| Hydrochloric Acid SCHEMBL29384552 | 0.87 | HTR1D (0.97) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| Clonidine SCHEMBL2231324 | 0.87 | ADRA2A (1.00) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| Clonidine SCHEMBL613364 | 0.87 | ADRA2A (0.97) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| Clonidine SCHEMBL40752 | 0.87 | ADRA2A (1.00) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| Clonidine SCHEMBL9838990 | 0.87 | ADRA2A (0.97) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| Clonidine SCHEMBL18050245 | 0.84 | ADRA2A (0.82) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL9920135 | 0.82 | ADRA2A (0.79) | ADRA2AADRA2CADRA2BADRA1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021019350-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF ANAL AND RECTAL DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2021-02-04 | — | — | WO | disclosed |
| US-20160152572-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-06-02 | — | — | US | disclosed |
| US-7884122-B2 | administering a2-adrenergic receptor agonist (clonidine) in hydrophilic matrix comprising hydroxypropyl methylcellulose ether, starch, and sodium lauryl sulfate; attention deficit disorder | SHIONOGI PHARMA, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100209510-A1 | Extended Release Formulation and Method of Treating Adrenergic Dysregulation | SHIONOGI INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100063123-A1 | EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION | ADDRENEX PHARMACEUTICALS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20090087490-A1 | EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION | ADDRENEX PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-4389403-A | HYPOTENSIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1983-06-21 | — | — | US | disclosed |
| EP-0037471-A1 | 1-Aroyl-2-phenylamino-2-imidazolines, their preparation and their pharmaceutical compositions | BASF Aktiengesellschaft (DE) | 1981-10-14 | — | — | EP | disclosed |
| EP-0004529-B1 | TANTOMERIC ARYLAMINOIMIDAZOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS FOR ANALGETIC APPLICATION CONTAINING THEM | Lentia Gesellschaft mit beschränkter Haftung (DE) | 1981-06-17 | — | — | EP | disclosed |
| EP-0004529-A2 | Tantomeric arylaminoimidazoline derivatives, their preparation and pharmaceutical formulations for analgetic application containing them | Lentia Gesellschaft mit beschränkter Haftung (DE) | 1979-10-17 | — | — | EP | disclosed |
| US-4142051-A | Arylaminoimidazoline derivatives | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1979-02-27 | — | — | US | disclosed |
| US-4094964-A | IMMUNOASSAY, HAPTEN, ANTIGEN | HOFFMANN-LA ROCHE INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-4025607-A | ANALGESICS, HYPOTENSIVES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-05-24 | — | — | US | disclosed |
| US-3950523-A | ANTIDEPRESSANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-04-13 | — | — | US | disclosed |
| US-3931216-A | Process for the manufacture of 2-arylamino-2-imidazoline derivatives and their salts | BOEHRINGER INGELHEIM GMBH (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063123-A1 | EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION | ADRA2A, ADRB2, ADRB1 | ADRA2A 1/4885ADRA2C 4/4885ADRA2B 5/4885 |
| US-20090087490-A1 | EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION | ADRB2, ADRA2A, ADRB1 | ADRA2A 2/4885ADRA2C 4/4885ADRA2B 5/4885 |
| US-20160152572-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS | SI, MUC1, ALPI | ADRA2A 1942/4885ADRA2C 977/4885ADRA2B 1580/4885 |
| US-20100209510-A1 | Extended Release Formulation and Method of Treating Adrenergic Dysregulation | ADRB2, ADRA2A, ADRB1 | ADRA2A 2/4885ADRA2C 4/4885ADRA2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.